Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway

Cell Death and Disease

Volumn 5, Issue 11, 2014, Pages

  Ohoka, N ^a   Nagai, K ^b   Hattori, T ^a   Okuhira, K ^a   Shibata, N ^a   Cho, N ^b   Naito, M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; REGULATOR PROTEIN; SNIPER(TACC3); TRANSFORMING ACIDIC COILED COIL 3; UBIQUITIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BESTATIN; KHR PROTEIN, S CEREVISIAE; LEUCINE; MICROTUBULE ASSOCIATED PROTEIN; MOLECULAR LIBRARY; SACCHAROMYCES CEREVISIAE PROTEIN; TACC3 PROTEIN, HUMAN; YEAST KILLER FACTOR;

ARTICLE; CANCER CELL; CELL DEATH; EXPRESSION VECTOR; HUMAN; HUMAN CELL; NERVE CELL DIFFERENTIATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UBIQUITINATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HT 29 CELL LINE; MCF 7 CELL LINE; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; PHARMACOLOGY; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; KILLER FACTORS, YEAST; LEUCINE; MCF-7 CELLS; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR TARGETED THERAPY; PROTEASOME ENDOPEPTIDASE COMPLEX; SACCHAROMYCES CEREVISIAE PROTEINS; SMALL MOLECULE LIBRARIES; UBIQUITIN; UBIQUITINATION;

EID: 84925655418     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.471     Document Type: Article

References (44)

1. Sudakin V, Yen TJ. Targeting mitosis for anti-cancer therapy. BioDrugs 2007; 21: 225-233.
2. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10: 825-841.
3. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007; 7: 107-117.
4. Hood FE, Royle SJ. Pulling it together: the mitotic function of TACC3. Bioarchitecture 2011; 1: 105-109.
5. Gergely F, Karlsson C, Still I, Cowell J, Kilmartin J, Raff JW. The TACC domain identifies a family of centrosomal proteins that can interact with microtubules. Proc Natl Acad Sci USA 2000; 97: 14352-14357.
6. LeRoy PJ, Hunter JJ, Hoar KM, Burke KE, Shinde V, Ruan J et al. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res 2007; 67: 5362-5370.
7. Lin CH, Hu CK, Shih HM. Clathrin heavy chain mediates TACC3 targeting to mitotic spindles to ensure spindle stability. J Cell Biol 2010; 189: 1097-1105.
8. Booth DG, Hood FE, Prior IA, Royle SJ. A TACC3/ch-TOG/clathrin complex stabilises kinetochore fibres by inter-microtubule bridging. EMBO J 2011; 30: 906-919.
9. Fu W, Tao W, Zheng P, Fu J, Bian M, Jiang Q et al. Clathrin recruits phosphorylated TACC3 to spindle poles for bipolar spindle assembly and chromosome alignment. J Cell Sci 2010; 123(Pt 21): 3645-3651.
10. Lioutas A, Vernos I. Aurora A kinase and its substrate TACC3 are required for central spindle assembly. EMBO Rep 2013; 14: 829-836.
11. Hood FE, Williams SJ, Burgess SG, Richards MW, Roth D, Straube A et al. Coordination of adjacent domains mediates TACC3-ch-TOG-clathrin assembly and mitotic spindle binding. J Cell Biol 2013; 202: 463-478.
12. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 5974-5979.
13. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005; 65: 767-779.
14. Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, Black JD et al. Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health 2005; 5: 8.
15. Kimura M, Yoshioka T, Saio M, Banno Y, Nagaoka H, Okano Y. Mitotic catastrophe and cell death induced by depletion of centrosomal proteins. Cell Death Dis 2013; 4: e603.
16. Piekorz RP, Hoffmeyer A, Duntsch CD, McKay C, Nakajima H, Sexl V et al. The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J 2002; 21: 653-664.
17. Schmidt S, Schneider L, Essmann F, Cirstea IC, Kuck F, Kletke A et al. The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program. Oncogene 2010; 29: 6184-6192.
18. Schneider L, Essmann F, Kletke A, Rio P, Hanenberg H, Schulze-Osthoff K et al. TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21WAF-mediated cell cycle arrest. Oncogene 2008; 27: 116-125.
19. Schneider L, Essmann F, Kletke A, Rio P, Hanenberg H, Wetzel W et al. The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival. J Biol Chem 2007; 282: 29273-29283.
20. Yao R, Natsume Y, Noda T. TACC3 is required for the proper mitosis of sclerotome mesenchymal cells during formation of the axial skeleton. Cancer Sci 2007; 98: 555-562.
21. Yao R, Natsume Y, Saiki Y, Shioya H, Takeuchi K, Yamori T et al. Disruption of Tacc3 function leads to in vivo tumor regression. Oncogene 2012; 31: 135-148.
22. Okuhira K, Ohoka N, Sai K, Nishimaki-Mogami T, Itoh Y, Ishikawa M et al. Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. FEBS Lett 2011; 585: 1147-1152.
23. Itoh Y, Ishikawa M, Naito M, Hashimoto Y. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. J Am Chem Soc 2010; 132: 5820-5826.
24. Itoh Y, Kitaguchi R, Ishikawa M, Naito M, Hashimoto Y. Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. Bioorg Med Chem 2011; 19: 6768-6778.
25. Itoh Y, Ishikawa M, Kitaguchi R, Sato S, Naito M, Hashimoto Y. Development of target protein-selective degradation inducer for protein knockdown. Bioorg Med Chem 2011; 19: 3229-3241.
26. Itoh Y, Ishikawa M, Kitaguchi R, Okuhira K, Naito M, Hashimoto Y. Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist. Bioorg Med Chem Lett 2012; 22: 4453-4457.
27. Demizu Y, Okuhira K, Motoi H, Ohno A, Shoda T, Fukuhara K et al. Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy. Bioorg Med Chem Lett 2012; 22: 1793-1796.
28. Okuhira K, Demizu Y, Hattori T, Ohoka N, Shibata N, Nishimaki-Mogami T et al. Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells. Cancer Sci 2013; 24: 87-89.
29. Sekine K, Takubo K, Kikuchi R, Nishimoto M, Kitagawa M, Abe F et al. Small molecules destabilize cIAP1 by activating auto-ubiquitylation. J Biol Chem 2008; 283: 8961-8968.
30. Jeng JC, Lin YM, Lin CH, Shih HM. Cdh1 controls the stability of TACC3. Cell Cycle 2009; 8: 3529-3536.
31. Peters JM. The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 2006; 7: 644-656.
32. Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 2013; 341: 84-87.
33. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9(3): 153-166.
34. Ha GH, Kim JL, Breuer EK. Transforming acidic coiled-coil proteins (TACCs) in human cancer. Cancer Lett 2013; 336: 24-33.
35. Cappell KM, Sinnott R, Taus P, Maxfield K, Scarbrough M, Whitehurst AW. Multiple cancer testis antigens function to support tumor cell mitotic fidelity. Mol Cell Biol 2012; 32: 4131-4140.
36. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013; 45: 1459-1463.
37. Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010; 42: 415-419.
38. Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 2013; 123: 855-865.
39. Shinmura K, Kato H, Matsuura S, Inoue Y, Igarashi H, Nagura K et al. A novel somatic FGFR3 mutation in primary lung cancer. Oncol Rep 2014; 31: 1219-1224.
40. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337: 1231-1235.
41. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013; 22: 795-803.
42. Yao R, Kondoh Y, Natsume Y, Yamanaka H, Inoue M, Toki H et al. A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells. Oncogene 2013; 33: 4242-4252.
43. Wurdak H, Zhu S, Min KH, Aimone L, Lairson LL, Watson J et al. A small molecule accelerates neuronal differentiation in the adult rat. Proc Natl Acad Sci USA 2010; 107: 16542-16547.
44. Ohoka N, Sakai S, Onozaki K, Nakanishi M, Hayashi H. Anaphase-promoting complex/cyclosome-cdh1 mediates the ubiquitination and degradation of TRB3. Biochem Biophys Res Commun 2010; 392: 289-294.